Journals | Policy | Permission

Cardiology Research

Review

Volume 15, Number 4, August 2024, pages 211-222

Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review

Cardiac amyloidosis (CA), an increasingly recognized condition within the realm of cardiology, is characterized by the extracellular deposition of amyloid fibrils in the heart, leading to restrictive cardiomyopathy (RCM) and substantial global health implications [1]. This condition primarily manifests as transthyretin (amyloid transthyretin (ATTR)) or immunoglobulin light chain (AL) amyloidosis, each posing unique diagnostic challenges and necessitating distinct therapeutic approaches [2].

CA is classified into several types, each with unique cardiac and extracardiac manifestations [3]. The three primary forms are AL amyloidosis and transthyretin amyloidosis, which includes wild-type (wild-type transthyretin amyloidosis (wtATTR)) and hereditary variants (hereditary transthyretin amyloidosis (hATTR)) [4]. AL amyloidosis, associated with plasma cell dyscrasias, is characterized by rapid progression and severe cardiac involvement, leading to high morbidity and mortality [5]. Transthyretin amyloidosis, on the other hand, often presents in an older population, manifesting predominantly as heart failure with preserved ejection fraction (HFpEF) and significant aortic stenosis [6].

wtATTR is frequently associated with aortic stenosis in elderly patients. This association is primarily due to the age-related accumulation of transthyretin amyloid deposits in the myocardium and aortic valve. The accumulation of amyloid in the aortic valve can contribute to the restriction of valve opening, thereby exacerbating aortic stenosis. Studies have shown that wtATTR is prevalent among patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis, suggesting a pathological link rather than a mere coincidence [7]. The amyloid deposits increase the stiffness of the valve and myocardial tissue, leading to decreased compliance and worsening of diastolic function, which further complicates the clinical management of these patients [8]. Understanding this relationship is crucial for early diagnosis and appropriate management of wtATTR in patients with aortic stenosis. By clearly elucidating the connection between wtATTR and aortic stenosis, this review aims to provide a comprehensive understanding of the pathophysiology and clinical implications of CA, thereby enhancing the management strategies for affected patients.

AL amyloidosis requires specific attention due to its distinct pathophysiology and treatment strategies. The primary treatment for AL amyloidosis involves chemotherapy regimens that target the underlying plasma cell dyscrasia, such as bortezomib, lenalidomide, and dexamethasone [7]. Autologous stem cell transplantation is also a treatment option for eligible patients, offering potential remission and improved survival rates [8]. The management of cardiac involvement in AL amyloidosis includes the use of heart failure medications, though these must be carefully tailored due to the unique challenges posed by amyloid infiltration in the myocardium [9].

In contrast, the treatment of ATTR amyloidosis has seen the advent of novel therapies like tafamidis, patisiran, and vutrisiran, which target the production and stabilization of transthyretin to prevent amyloid fibril formation and deposition [10]. These therapies offer a different mechanism of action compared to those used for AL amyloidosis, highlighting the need for distinct treatment pathways based on the type of amyloidosis diagnosed.

Recent clinical experiences highlight the complexity of diagnosing and treating CA. For instance, patients often present with nonspecific symptoms such as fatigue and edema, which can lead to misdiagnosis or delayed diagnosis. Advanced imaging techniques, such as echocardiography with strain imaging and cardiac magnetic resonance imaging (CMR), are pivotal in early detection and assessment of the extent of cardiac involvement [7]. Additionally, novel diagnostic tools like bone scintigraphy using 99mTc-pyrophosphate (99mTc-PYP) have shown high sensitivity and specificity for detecting transthyretin amyloidosis, further aiding in differentiating it from AL amyloidosis [8].

From a therapeutic perspective, the management of CA has evolved significantly. Therapies such as tafamidis, patisiran, and vutrisiran have shown promising results in clinical trials, offering hope for improved patient outcomes. However, these treatments come with challenges, including high costs and limited availability, which can impact their accessibility and overall effectiveness in real-world settings [9]. Clinicians must navigate these challenges while considering each patient’s unique clinical presentation and disease progression to optimize treatment strategies.

Through this review, we aim to provide a comprehensive and clinically relevant discussion on the pathophysiology, diagnosis, and management of CA. Our goal is to offer insights that can guide healthcare professionals in making informed decisions, ultimately improving patient care and outcomes in this challenging field.

The pathogenesis of CA involves the misfolding of protein precursors, leading to fibril formation and deposition in cardiac tissues [7]. This deposition disrupts myocardial structure and function, culminating in heart failure and arrhythmic complications [8]. Recent epidemiological data highlight a notable underdiagnosis of this condition, particularly among older adults presenting with HFpEF, where systematic screenings have revealed a prevalence as high as 16% in certain cohorts [9].

Despite the severity of the condition, recent years have witnessed significant advancements in the therapeutic landscape of CA [10]. Gene silencing therapies, such as patisiran and vutrisiran, target the RNA transcripts of amyloidogenic proteins, reducing their production and potentially altering the course of the disease [11]. Additionally, stabilizing agents like tafamidis have shown promise in managing TTR variants by preventing protein misfolding and deposition [12].

The increasing recognition of CA has not only improved our understanding of its clinical presentation but also highlighted the variability in outcomes and discrepancies in the availability of treatment options across different regions and populations [13]. This review seeks to consolidate current knowledge on the diagnosis, management, and outcomes of CA, with an emphasis on elucidating the pathophysiological mechanisms, optimizing therapeutic strategies, and addressing gaps in current research paradigms.

Thus, the objectives of this review are twofold: to provide a comprehensive overview of the contemporary diagnostic and management approaches in CA and to set a direction for future research that could potentially lead to groundbreaking advancements in the care of patients suffering from this debilitating condition. Through this exploration, we aim to foster a deeper understanding of CA, from its molecular underpinnings to its clinical implications, thereby improving patient outcomes and contributing to the global efforts in combating this intricate disease.

CA, a form of cardiomyopathy primarily driven by the accumulation of amyloid proteins within the heart, manifests predominantly through transthyretin or immunoglobulin light chains [3]. The three major forms of CA identified are wtATTR, hATTR, and AL amyloidosis [4].

Recent epidemiological data suggest a notable underdiagnosis of wtATTR, particularly among older adults presenting with HFpEF and severe aortic stenosis [14]. Systematic screenings in such cohorts reveal a prevalence of approximately 6% in individuals over 60 years of age with HFpEF, compared to a mere 1% detected without dedicated screening [15]. Similar studies conducted in hospital settings on patients with HFpEF indicate a prevalence of 13%, and among those undergoing transcatheter aortic valve implantation for aortic stenosis, the detection rate of wtATTR amyloidosis climbs to 16% [16].

The epidemiology of hATTR (or ATTR variant (ATTRv)) remains less clear due to its association with over 120 pathogenic gene variants, each exhibiting varying geographical and ethnic prevalence [17]. Common mutations such as Val122Ile and Val30Met suggest a distinct genetic predisposition linked to specific populations, influencing the regional distribution of this amyloidosis type [18].

AL amyloidosis, although rare with an incidence of approximately one per 100,000 annually in the United States, is associated with plasma cell dyscrasias [19]. This form presents a critical need for enhanced diagnostic awareness due to its severe prognostic implications if left unidentified [20].

Demographically, recent insights indicate an increase in the prevalence and incidence of CA globally, with particular emphasis on the elderly and male populations [21]. This is corroborated by findings from autopsies and clinical screenings which suggest that CA, particularly transthyretin amyloid cardiomyopathy (ATTR-CM), may be significantly more prevalent than previously recognized in the aging population [22]. Ethnic and racial disparities also emerge in the manifestation and progression of the disease, with non-Hispanic Blacks and Hispanics exhibiting more aggressive disease phenotypes and higher hospitalization rates compared to Whites [23].

Understanding these epidemiological trends is essential for framing public health strategies and clinical approaches, aiming to enhance screening and early diagnosis, especially in high-risk groups. This is critical not only for improving outcomes through timely interventions but also for addressing disparities in the detection and management of CA across different demographic groups.

CA is characterized by the extracellular deposition of misfolded proteins in the myocardium, which results in RCM and progressive heart failure [24]. The pathophysiology of this disease involves complex molecular and biochemical mechanisms centered around the misfolding and aggregation of specific proteins, primarily transthyretin in ATTR and immunoglobulin light chains in AL [25].

In ATTR, genetic mutations such as Val122Ile, Thr60Ala, and Glu89Gln destabilize TTR tetramers, facilitating their dissociation into monomeric forms that are prone to misfold [26]. These misfolded proteins then aggregate into amyloid fibrils, which deposit in the cardiac extracellular matrix [27]. Similarly, in AL amyloidosis, abnormal immunoglobulin light chains produced by clonal plasma cells fold improperly and form amyloid fibrils [28].

Once deposited, these amyloid fibrils disrupt the structural integrity and functional capacity of the heart [29]. They interfere with the alignment and organization of cardiac muscle fibers, increase myocardial stiffness, and reduce elasticity [30]. This mechanical disruption leads to diastolic dysfunction as the heart becomes less compliant and unable to fill effectively during diastole [31]. Additionally, amyloid fibrils bind to cellular components such as receptors and enzymes, impairing intracellular signaling and metabolic processes, and disrupting ionic homeostasis [7]. The presence of amyloid also triggers an inflammatory response in the heart, marked by activation of cardiac fibroblasts and infiltration of inflammatory cells, contributing to further myocardial damage and fibrosis [32].

These pathophysiological changes culminate in progressive heart failure with symptoms such as dyspnea, fatigue, and edema [13]. Moreover, amyloid infiltration into the cardiac conduction system can lead to various arrhythmias, including atrial fibrillation (AF) and conduction blocks, further reducing cardiac output and increasing the risk of thromboembolic events [33].

Understanding these pathophysiological processes is crucial for the clinical management of CA and guides the development of therapeutic strategies [7]. One such strategy includes gene silencing therapies like patisiran, which target the production of amyloidogenic proteins at the transcriptional level [34]. By reducing the amount of mutant and wild-type TTR, these therapies aim to lessen the substrate available for amyloid formation [35]. The pathophysiological insights into how amyloid fibrils affect cardiac function support the use of such therapies, which, although they do not remove existing deposits, can prevent the formation of new amyloid accumulations and potentially ameliorate symptoms and disease progression [7].

Thus, the molecular and cellular mechanisms underlying the deposition of amyloid fibrils and their impact on cardiac tissues are fundamental to diagnosing and developing interventions for CA [36]. Further research into these mechanisms is essential for creating therapies that not only alleviate symptoms but also modify the underlying disease dynamics.

CA manifests through a spectrum of symptoms that vary depending on the type of amyloid protein involved and the extent of cardiac infiltration [37]. This condition, characterized by the deposition of amyloid proteins in the heart, leads to significant clinical challenges due to its diverse presentations and the progressive nature of the disease [38].

Patients with ATTR amyloidosis, whether hereditary or wild type, typically present in the later decades of life, with symptoms emerging predominantly after the age of 60 [39]. The clinical phenotype includes features of RCM such as dyspnea on exertion, fatigue, and lower extremity edema, reflecting the underlying heart failure caused by impaired ventricular filling and reduced diastolic function of the heart [13]. These symptoms are often more pronounced in patients with wild-type ATTR amyloidosis and certain hereditary variants, where cardiac involvement is the dominant clinical feature [5].

In contrast, AL amyloidosis affects patients usually beginning at age 40, with a wider range of organ involvement [40]. In addition to cardiac symptoms, patients may exhibit manifestations related to renal, neurological, and gastrointestinal involvement [3]. Cardiac-specific symptoms in AL amyloidosis tend to be severe due to the toxic effects of amyloidogenic light chains on myocardial cells, which can exacerbate cardiac dysfunction [13].

Common cardiac manifestations in all forms of amyloidosis include increased jugular venous pressure, hepatic congestion, and ascites associated with right ventricular failure [14]. Advanced disease stages are characterized by features of low cardiac output such as diminished pulse pressure and delayed capillary refill, indicating severe cardiac compromise [41].

Arrhythmias are a prevalent complication, with patients frequently presenting with syncope or presyncope [42]. These episodes are typically caused by bradyarrhythmias or advanced atrioventricular block, though ventricular arrhythmias can also occur [43]. The need for pacemaker implantation is common, especially in patients with ATTR amyloidosis due to progressive conduction system disease [44].

Electrocardiographic findings in CA often reveal a low voltage in the limb leads and a pseudoinfarct pattern in the precordial leads, despite echocardiographic evidence of increased left ventricular wall thickness [45]. This discordance is a notable diagnostic clue but varies in sensitivity depending on the amyloid type [20]. Echocardiography typically shows increased wall thickness, biatrial enlargement, and signs of diastolic dysfunction [46]. These imaging findings are crucial for assessing the severity and extent of myocardial involvement [47].

AF is another common finding, especially in patients with wtATTR amyloidosis, and is associated with an increased risk of thromboembolic events [33]. The deposition of amyloid proteins not only in the ventricles but also in the atrial walls can lead to atrial electromechanical dissociation during sinus rhythm, which further complicates the clinical picture [44].

In summary, the clinical manifestations of CA are complex and varied, often involving a combination of heart failure symptoms, arrhythmias, and conduction system abnormalities. The diagnosis is challenging due to the nonspecific nature of early symptoms and the multifaceted presentations that depend heavily on the type and extent of amyloid deposition within the heart. Early recognition and detailed cardiovascular evaluation are critical to managing this intricate and progressively debilitating disease.

CA presents significant challenges in clinical management due to its diverse array of complications, which predominantly affect the heart’s electrical system and mechanical function [48]. This disease process leads to substantial morbidity and mortality, primarily from AF, conduction system disease, heart failure, and sudden cardiac death (SCD) [49].

AF is notably prevalent in patients with ATTR-CA, occurring in up to 73% of cases. This high incidence is linked with older age, advanced disease stage, and increased left atrial volume index. The management of AF in this group is complicated by the high risk of thromboembolic events and the poor tolerance of rate control medications, often necessitating early adoption of rhythm control strategies [50]. Although anticoagulation therapy is crucial for preventing strokes in these patients, recent studies indicate that novel oral anticoagulants (NOACs) are associated with a lower risk of major bleeding compared to warfarin, while both options effectively reduce the incidence of thromboembolic events [50]. Furthermore, AF ablation appears to reduce mortality and hospitalization for heart failure when performed early, emphasizing the need for prompt and tailored treatment interventions [51].

Conduction system disease also emerges as a frequent complication due to amyloid fibril deposition within the myocardium. This deposition can lead to bundle branch blocks, atrioventricular block, or sick sinus syndrome. Management often requires the implantation of pacemakers, especially in patients exhibiting advanced conduction disorders [52]. However, the timing for such interventions is critical and demands careful clinical judgment to balance the benefits against potential risks. Moreover, standard arrhythmic drugs like beta-blockers and calcium-channel blockers are typically poorly tolerated in this patient population, complicating traditional therapeutic approaches [25].

Heart failure in CA is predominantly driven by RCM due to amyloid infiltration in the myocardial extracellular space. This condition leads to both diastolic and, eventually, systolic dysfunction as the disease progresses [24]. The management of heart failure in these patients is intricate, requiring a combination of standard heart failure therapies and novel disease-modifying treatments that aim to slow or halt the progression of amyloid deposition. Challenges include the systemic nature of the disease and the need for a multidisciplinary approach to address the complex clinical presentation [53].

SCD is a grave risk for patients with CA, with ventricular arrhythmias and electromechanical dissociation being primary contributors. While implantable cardioverter-defibrillators (ICDs) have been used for the prevention of SCD, their effectiveness in improving overall survival in this group remains uncertain [54]. This uncertainty is partly due to the high mortality rate observed despite ICD therapy and the complex interplay of risk factors including ventricular tachyarrhythmias, which may not be adequately managed by ICDs alone. Noninvasive measures of myocardial energy metabolism have been explored as potential tools for predicting SCD risk, suggesting that metabolic imaging could play a role in risk stratification [55].

In conclusion, the complications associated with CA necessitate a nuanced understanding of its pathophysiological impact on cardiac function and a comprehensive approach to management that integrates both symptomatic treatment and strategies aimed at modifying the underlying disease process. The intricate interplay of electrical and mechanical dysfunction requires targeted interventions to mitigate the high risk of morbidity and mortality in this patient population.

CA is a complex condition characterized by the deposition of amyloid proteins in the myocardium, leading to varied and often nonspecific clinical presentations that can challenge timely and accurate diagnosis. This section outlines the diagnostic criteria and challenges associated with identifying CA, emphasizing the systematic approaches required to confirm this condition [24].

The suspicion of CA should be raised in several clinical settings, particularly in patients presenting with unexplained left ventricular hypertrophy (LVH), whether they exhibit heart failure symptoms or not. Such cases necessitate a detailed clinical evaluation including a thorough history to note any presence of bilateral carpal tunnel syndrome before the onset of heart failure, which is suggestive of ATTR amyloidosis [56]. Other scenarios warranting suspicion include instances of low-flow, low-gradient aortic stenosis coupled with echocardiographic signs of impaired longitudinal strain and conditions like systemic AL amyloidosis or ATTR-related peripheral neuropathy, where cardiac involvement may often be secondary [57].

Once clinical suspicion is established, a structured diagnostic approach is vital. The initial evaluation should integrate a comprehensive clinical examination, detailed family and medical history, routine laboratory tests, and an electrocardiogram to identify cardiac and extracardiac symptoms and signs indicative of amyloidosis [58]. Subsequently, echocardiography serves as the principal noninvasive imaging modality, offering crucial insights such as the presence of a granular “sparkling” texture of the myocardium, biatrial enlargement, and thickening of the valves and interatrial septum. Notably, the echocardiographic finding of relative apical sparing of longitudinal strain is highly suggestive of CA and can aid in differentiating it from other causes of LVH [59].

Apical sparing refers to the preservation of myocardial strain in the apical segments of the heart while the basal and mid segments show reduced strain. This pattern is thought to result from the predilection of amyloid deposits to affect the basal and mid segments more extensively than the apex. The exact mechanisms are not fully understood, but it is hypothesized that variations in myocardial blood flow, amyloid deposition patterns, and differences in myocardial fiber orientation contribute to this phenomenon [60]. By highlighting these echocardiographic features and explaining their underlying mechanisms, this review aims to enhance the diagnostic accuracy and clinical understanding of CA, thereby improving patient management and outcomes.

Further imaging assessments may include cardiovascular magnetic resonance (CMR), which provides detailed myocardial tissue characterization. CMR is particularly useful in visualizing the diffuse subendocardial or transmural late gadolinium enhancement typical of CA. Additionally, T1 mapping during CMR can provide quantitative measures that correlate strongly with the extent of amyloid infiltration, thus supporting the diagnosis even in early stages [60].

Bone tracer cardiac scintigraphy using radiotracers like 99mTc-PYP plays a critical role in diagnosing ATTR CA. A significant uptake in these scans, especially in the absence of a monoclonal protein indicative of plasma cell dyscrasia, can confirm ATTR without the need for tissue biopsy [61]. However, when the presence of monoclonal proteins is detected, further hematological evaluation and possibly a bone marrow biopsy are necessary to differentiate AL from ATTR amyloidosis or other forms such as amyloid A (AA) amyloidosis [13].

In cases where the noninvasive diagnostic modalities are inconclusive, or clinical suspicion remains high despite negative findings, tissue biopsy remains the gold standard. This invasive procedure, typically involving an endomyocardial biopsy, allows for direct visualization and typing of amyloid deposits using Congo red staining, which exhibits apple-green birefringence under polarized light, and further confirmation through immunohistochemical or mass spectrometric methods to determine the precise type of amyloid protein involved [40].

In conclusion, diagnosing CA requires a high index of clinical suspicion prompted by specific clinical and laboratory indicators, followed by a systematic approach utilizing echocardiography, CMR, and bone scintigraphy to identify the disease. In ambiguous cases, tissue biopsy confirms the diagnosis, allowing for appropriate management and therapeutic interventions tailored to the type of amyloidosis identified.

The differential diagnosis of CA involves a detailed examination to distinguish it from conditions with similar clinical presentations, such as hypertrophic cardiomyopathy (HCM), constrictive pericarditis, and other forms of RCM, including sarcoidosis and light chain deposition disease [62]. Each of these conditions presents unique diagnostic challenges and requires specific investigative approaches to ensure accurate diagnosis and appropriate management [63].

HCM often presents with asymmetric septal hypertrophy, predominantly affecting the interventricular septum, and may involve genetic markers and family history elements absent in amyloidosis. Echocardiographic examination in CA typically reveals symmetrical left ventricular wall thickening with a granular sparkling appearance, distinguishing it from the asymmetrical thickening observed in HCM. Advanced imaging techniques, such as strain imaging, can further enhance differentiation, showing a relative apical sparing of longitudinal strain in CA, a pattern rarely observed in HCM [62].

Constrictive pericarditis, characterized by a thickened, calcified pericardium on imaging modalities such as computed tomography (CT) or magnetic resonance imaging (MRI), shows distinct hemodynamic features from CA. These include ventricular interdependence and a dip-and-plateau filling pattern of the ventricles, identifiable through echocardiography and CMR. In contrast, CA does not exhibit these pericardial abnormalities but may show biatrial enlargement and ventricular thickening consistent with infiltrative processes [64].

RCM other than amyloidosis, such as endomyocardial fibrosis or Loeffler’s syndrome, presents with fibrosis and eosinophilic infiltration distinct from the amyloid fibrils seen in CA. Histological findings from biopsies in RCM reveal specific patterns of fibrosis without the characteristic apple-green birefringence under polarized light, which is indicative of amyloid deposits in CA [65].

Sarcoidosis involves non-caseating granulomas identifiable on myocardial biopsy, which are absent in CA. Diagnostic criteria for cardiac sarcoidosis include advanced imaging findings such as positron emission tomography (PET) scans, which detect inflammatory activity not present in amyloidosis, aiding in their differentiation [66].

Light chain deposition disease differs from CA in that the light chain deposits do not form fibrils and, thus, do not exhibit the Congo red positivity seen in CA. Immunofluorescence or immunohistochemistry typically shows positivity for specific light chains in structures like the glomerular basement membrane, contrasting with the diffuse and extensive deposition in CA [67, 68].

HFpEF and CA can both present with diastolic dysfunction and similar echocardiographic findings. However, distinguishing these conditions may rely on clinical context, biomarker profiles, and response to treatment, where specific markers like N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiographic indices such as strain patterns may help in differentiation [69].

A comprehensive diagnostic approach, integrating clinical evaluation, detailed imaging studies, and histopathological analysis, is essential to accurately differentiate CA from other mimicking conditions [70]. This systematic approach ensures that CA is appropriately diagnosed and managed, taking into consideration the complex interplay of clinical presentations and the specific characteristics of each condition.

The management of CA encompasses a broad spectrum of strategies, from pharmacological interventions and gene silencing therapies to supportive care and advanced treatment options like heart transplantation. This comprehensive approach is essential due to the complex nature of CA, which involves the deposition of amyloid proteins in the heart, leading to RCM and heart failure [71].

Ongoing surveillance of disease progression in CA is critical. This is typically achieved through a combination of biomarker assessments, including natriuretic peptides and troponins, which provide prognostic information. Cardiac imaging plays a pivotal role, with techniques such as echocardiography and CMR being integral for assessing myocardial structure and function. Advanced imaging modalities, including technetium-labeled bone scintigraphy, are increasingly utilized not only for diagnosis but also for monitoring response to therapy [72].

The pharmacological management of CA must be approached with caution. Traditional heart failure medications often pose risks due to patients’ sensitivity to volume changes and reduced cardiac output. In AL CA, common medications such as beta-blockers and calcium channel blockers may exacerbate heart failure symptoms or lead to adverse events due to their hemodynamic effects. Consequently, these agents are generally avoided or used with stringent monitoring [44].

Tafamidis has emerged as a cornerstone in the management of ATTR amyloidosis, stabilizing the transthyretin protein and preventing its misfolding and deposition as amyloid fibrils. Recent advancements have introduced gene silencing therapies that target the production of transthyretin at the RNA level, offering new hope for directly addressing the underlying pathophysiology of ATTR [73].

Acoramidis, a novel therapeutic agent, is garnering attention in the landscape of ATTR-CM management, particularly for its potential to effectively stabilize TTR tetramers. Unlike tafamidis, which shares a similar mechanism, acoramidis has demonstrated promising results in recent clinical trials. It significantly lowers hospitalization rates and offers some improvement in exercise capacity and quality of life for patients with ATTR CA. Although mortality rates did not differ significantly from those observed with placebo, the nuanced benefits in managing symptoms and potentially delaying progression provide a meaningful therapeutic option. Importantly, the robust in vitro evidence supporting acoramidis’s capacity to achieve near-complete TTR stabilization suggests its superior effectiveness over tafamidis, particularly across various genetic forms of the disease. This broad efficacy implies that acoramidis could offer a substantial clinical advantage, contributing to the evolving therapeutic strategies aimed at mitigating the burdensome effects of ATTR [74].

Among the most promising advancements in the treatment of CA are gene silencing therapies such as patisiran and vutrisiran. These therapies utilize mechanisms of RNA interference to reduce the hepatic synthesis of transthyretin, thereby diminishing the amyloid burden in the myocardium. Recent clinical trials have shown that patisiran can significantly improve cardiac markers and quality of life, although its impact on mortality and hospitalization requires further investigation [75, 76].

For patients with refractory CA, options such as heart transplantation may be considered, though the feasibility depends on the patient’s overall health and the specific type of amyloidosis. Mechanical circulatory support devices are less commonly used due to technical challenges related to the myocardial infiltration by amyloid [77].

Management also includes non-pharmacological strategies such as dietary modifications, fluid management, and avoidance of alcohol and tobacco. In selected cases, surgical interventions may be necessary to address specific complications arising from amyloid deposition in the heart [78].

The timing of interventions in CA management significantly affects patient outcomes. Early intervention with therapies like tafamidis, patisiran, or vutrisiran, when cardiac function is less compromised, can slow disease progression and improve prognosis. Conversely, advanced-stage interventions may focus more on symptom management and supportive care. This underscores the importance of early diagnosis and timely therapeutic intervention to optimize patient outcomes [79].

The landscape of CA management is evolving rapidly, with gene silencing therapies at the forefront of this transformation. These treatments offer a mechanism-based approach to reduce the production of amyloidogenic proteins and potentially reverse some of the cardiac damage [79]. As research progresses, the integration of these new therapies with traditional approaches promises to enhance outcomes for patients suffering from this challenging and often fatal condition.

To provide a comprehensive overview, we have included Table 1 [73-76], summarizing recent therapies introduced in clinical trials, detailing the number of participants, outcomes related to survival and stabilization, and primary trial findings.

Click to view

Table 1. Recent Therapies in Clinical Trials for Cardiac Amyloidosis

One very major problem with the new therapies is the cost, which should be considered in light of their limited effect on survival. The cost of therapies such as tafamidis, patisiran, and vutrisiran can be substantial, potentially limiting their accessibility. Tafamidis, for example, is known to be priced at around $225,000 per year, making it one of the most expensive cardiovascular drugs on the market. Patisiran and vutrisiran, while promising, also come with high costs due to their novel RNA interference technology.

An economic analysis reveals that while these therapies can significantly improve the quality of life and reduce hospitalizations, their cost-effectiveness is still under debate. For instance, tafamidis has been shown to reduce cardiovascular-related hospitalizations, but its impact on overall mortality is less pronounced. This brings into question the overall cost-benefit ratio, particularly for healthcare systems with limited resources.

In the context of a cost-benefit analysis, the primary benefits of these therapies include improved cardiac biomarkers, reduced symptoms, and better quality of life, which must be weighed against their financial burden. Policymakers and healthcare providers need to consider these factors when making decisions about the allocation of resources for the treatment of CA.

Addressing the high costs and ensuring broader access to these therapies will be crucial for maximizing their impact on patient outcomes. Future research should also focus on developing more cost-effective treatments and strategies to manage CA, which could provide significant benefits in terms of both health outcomes and economic sustainability.

The prognosis of CA varies significantly based on the type of amyloidosis, the stage at diagnosis, and the response to treatment. In AL amyloidosis with cardiac involvement, the median survival is approximately 5.5 years with contemporary management. Staging methods, such as the Mayo Clinic staging system, which incorporate biomarkers like NT-proBNP and cardiac troponin T, provide a robust framework for predicting survival. These systems demonstrate that higher biomarker levels correlate with more advanced disease and poorer outcomes [80].

In ATTR amyloidosis, both wild-type (ATTRwt) and variant (ATTRv), staging also relies heavily on NT-proBNP and troponin levels, but includes renal function as measured by estimated glomerular filtration rate (eGFR). Patients with ATTR amyloidosis show a median survival that varies significantly across stages; those in the earliest stage have a substantially longer survival compared to those in the most advanced stage. The staging system specifically for ATTRwt or ATTRv predicts median survival times of 69.2 months, 46.7 months, and 24.1 months for stages I, II, and III, respectively. This demonstrates a clear gradient of risk based on biomarker and renal function profiles [81].

The predictive factors influencing prognosis in CA are multifaceted. In AL amyloidosis, the Mayo staging system, hematologic response, and cardiac response are significant predictors of survival. Advanced disease stages and lack of early cardiac response, particularly in stage IIIb cardiac AL amyloidosis, are associated with shortened survival. Conversely, patients who achieve an early cardiac response often experience a prolonged survival, underscoring the importance of timely and effective treatment [82].

Imaging and biomarker studies are indispensable tools for prognostic assessment in CA. CMR, including techniques like late gadolinium enhancement and T1 mapping, provides critical information on myocardial involvement and fibrosis. Additionally, molecular imaging with PET and single-photon emission computed tomography (SPECT) facilitates early assessment of amyloid burden and disease progression [83-85].

Overall, the prognosis of CA depends on a complex interplay of disease subtype, stage at diagnosis, and therapeutic response. Advanced staging systems, coupled with the latest imaging and biomarker technologies, play a crucial role in enhancing prognostic accuracy, thereby guiding therapeutic decisions and improving patient management.

Despite significant advances in the diagnosis and management of CA, critical gaps in the literature persist, affecting our ability to effectively understand and treat this complex condition. These gaps span across early diagnosis, long-term treatment effects, and the integration of new diagnostic and therapeutic modalities [86].

In this regard, early diagnostic indicators for CA remain inadequately defined despite the known benefits of early detection in improving patient outcomes. While CMR with late gadolinium enhancement and advanced echocardiography techniques such as speckle tracking have shown promise, the sensitivity and specificity of these methods need further validation. Additionally, a comprehensive set of early “red flags” including clinical, biohumoral, and imaging features has been suggested to facilitate earlier diagnosis, yet a standardized diagnostic pathway incorporating these indicators has not been fully established [87].

Conversely, there are considerable gaps in understanding the long-term effects of treatments for CA. Although new medications like tafamidis have emerged, comprehensive data on their long-term effectiveness and safety are lacking. The literature calls for novel, non-toxic, and effective treatments for patients with advanced cardiac dysfunction due to amyloidosis, as current therapies are often associated with high rates of early mortality [88].

Furthermore, while the evolution of epidemiology and natural history of ATTR CA suggests some improvements in short-term outcomes such as the 2-year survival rate with contemporary diagnosis and treatment, comprehensive studies tracking long-term survival and quality of life are still lacking. This highlights the importance of early diagnosis and the timely initiation of disease-modifying treatments to potentially improve overall survival and patient outcomes [13].

Moreover, the literature indicates that while established biomarkers such as NT-proBNP and high-sensitivity troponin are valuable for the diagnosis of CA, there is a pressing need for the development and validation of novel biomarkers. Emerging technologies and biomarkers could potentially improve the early detection of CA, but gaps remain in their standardization and application in clinical practice [89].

In terms of imaging, although various noninvasive modalities like MRI, PET, and bone scintigraphy are instrumental in diagnosing CA, comparative studies to delineate their specific roles and improve diagnostic algorithms are needed. In particular, differentiation between the amyloidosis subtypes ATTR and AL remains challenging with current imaging techniques, underscoring the need for advances in this area [90].

In addition, the integration of genetic testing and personalized medicine into the management of CA represents another critical gap. While genetic testing has facilitated the diagnosis and management of ATTR-CM, comparative trials to clarify treatment options and understand the impact of genetic variations on treatment outcomes are deficient [91].

To address these gaps, future research should focus on developing standardized, sensitive, and specific diagnostic criteria that incorporate new biomarkers and imaging techniques. Additionally, longitudinal studies are necessary to evaluate the long-term efficacy and safety of new treatments. Finally, improving our understanding of the genetic aspects of amyloidosis will be critical to advancing personalized medicine approaches that could significantly impact treatment outcomes.

Future research and management of CA should focus on enhancing diagnosis, treatment, and patient outcomes. The emphasis is on developing noninvasive diagnostic methods, refining therapeutic options, and implementing comprehensive management strategies tailored to the disease’s complexities [92].

Advancements in imaging techniques and biomarkers are essential for early detection and accurate diagnosis of CA. Efforts should improve the specificity and sensitivity of CMR and bone scintigraphy to distinguish between ATTR and AL types without invasive biopsies. Additionally, integrating novel biomarkers into clinical practice could provide a better understanding of disease progression. These biomarkers should be validated through clinical trials to establish their roles in enhancing diagnostic accuracy and predicting treatment responses [93].

In the therapeutic domain, there is a need for treatments that slow amyloid deposition and potentially reverse cardiac tissue damage. Research should focus on refining existing therapies like tafamidis and exploring new drug classes, such as gene silencers and kinetic stabilizers. Combination therapy strategies could address the multifaceted nature of amyloidosis more effectively than monotherapy [94].

Clinical trials should evaluate the long-term efficacy and safety of emerging treatments, incorporating a range of clinical endpoints to provide a comprehensive assessment of therapeutic benefits. This will facilitate developing personalized treatment regimens considering individual patients’ genetic and biochemical makeup [95].

Enhancing patient management strategies is also crucial, including optimizing supportive care for heart failure symptoms and refining strategies for managing comorbidities such as AF and thromboembolic disease. Multidisciplinary teams are fundamental in providing comprehensive care that addresses patients’ diverse needs from diagnosis to advanced disease stages [96].

Collectively, these efforts in research and clinical practice aim to improve outcomes for patients suffering from CA.

CA, a condition marked by the extracellular deposition of amyloid fibrils in the heart, has garnered increasing attention due to its significant impact on global health and its complex management challenges. This review has synthesized key insights into the pathophysiology, epidemiology, and clinical management of the disease, particularly highlighting the underdiagnosed nature of transthyretin amyloidosis among elderly patients with heart failure. Recent advancements in gene silencing therapies offer a promising avenue for targeting the underlying mechanisms of amyloid production, potentially revolutionizing treatment paradigms. However, significant gaps remain in early diagnosis and long-term treatment efficacy. Given these challenges, there is a critical need for continued research and enhanced policy support to refine diagnostic strategies and develop effective treatments, ensuring better management and outcomes for patients suffering from this debilitating condition.

Acknowledgments

The authors have no acknowledgements to declare, reflecting the independent completion of the work.

Financial Disclosure

No funding was received for the conduct of this study or the preparation of this article, indicating that there are no financial sources to declare.

Conflict of Interest

The authors declare no conflict of interest to ensure the impartiality of the review.

Author Contributions

Jordan Llerena-Velastegui, MD: conceptualization, supervision, project administration, writing - review and editing. Kristina Zumbana-Podaneva: supervision, writing, review, and editing.

Data Availability

All data generated or analyzed during this study are included in this published article, and further inquiries should be directed to the corresponding author.

1. Razvi Y, Patel RK, Fontana M, Gillmore JD. Cardiac amyloidosis: A Review of Current Imaging Techniques. Front Cardiovasc Med. 2021;8:751293.
   doi pubmed pmc
2. Rubin J, Maurer MS. Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu Rev Med. 2020;71:203-219.
   doi pubmed
3. Ash S, Shorer E, Ramgobin D, Vo M, Gibbons J, Golamari R, Jain R, et al. Cardiac amyloidosis-A review of current literature for the practicing physician. Clin Cardiol. 2021;44(3):322-331.
   doi pubmed pmc
4. Jamal F, Rosenzweig M. Amyloidosis with cardiac involvement: identification, characterization, and management. Curr Hematol Malig Rep. 2021;16(4):357-366.
   doi pubmed pmc
5. Argon A, Nart D, Yilmazbarbet F. Cardiac amyloidosis: clinical features, pathogenesis, diagnosis, and treatment. Turk Patoloji Derg. 2024;40(1):1-9.
   doi pubmed pmc
6. Irabor B, McMillan JM, Fine NM. Assessment and management of older patients with transthyretin amyloidosis cardiomyopathy: geriatric cardiology, frailty assessment and beyond. Front Cardiovasc Med. 2022;9:863179.
   doi pubmed pmc
7. Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res. 2021;128(10):1554-1575.
   doi pubmed pmc
8. Salinas-Arce J, Alca-Clares R, Gonzales-Luna AC, Cabrera-Saldana M, Mendoza-Novoa P, Solorzano-Altamirano P, Guevara-Valdivia M. [Cardiac arrhythmias and amyloidosis]. Arch Peru Cardiol Cir Cardiovasc. 2022;3(2):82-97.
   doi pubmed pmc
9. Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, Sinagra G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022;24(12):2342-2351.
   doi pubmed pmc
10. Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol. 2023;20(5):361-375.
    doi pubmed pmc
11. Ioannou A, Fontana M, Gillmore JD. RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs. 2023;37(2):127-142.
    doi pubmed pmc
12. Nijst P, Tang WW. Recent advances in the diagnosis and management of amyloid cardiomyopathy. Fac Rev. 2021;10:31.
    doi pubmed pmc
13. Shams P, Ahmed I. Cardiac Amyloidosis. In: StatPearls. Treasure Island (FL). 2024.
    pubmed
14. Nazir T, Nuffati M. Cardiac amyloidosis-an underdiagnosed cause of heart failure in the elderly. J Saudi Heart Assoc. 2020;32(1):98-102.
    doi pubmed pmc
15. AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6(11):1267-1274.
    doi pubmed pmc
16. Joynt Maddox KE, Zhang KW. Cardiac amyloidosis: more than a needle in a haystack. JACC CardioOncol. 2020;2(5):719-720.
    doi pubmed pmc
17. Mouksian K, Ammon J, Pullen D, Zhang Q, Yedlapati N, Jefferies JL. Cardiac amyloidosis: a rare TTR mutation found in an Asian female. J Cardiovasc Dev Dis. 2023;10(1):13.
    doi pubmed pmc
18. Arno S, Cowger J. The genetics of cardiac amyloidosis. Heart Fail Rev. 2022;27(5):1485-1492.
    doi pubmed
19. Stelmach-Goldys A, Zaborek-Lyczba M, Lyczba J, Garus B, Pasiarski M, Mertowska P, Malkowska P, et al. Physiology, diagnosis and treatment of cardiac light chain amyloidosis. J Clin Med. 2022;11(4):911.
    doi pubmed pmc
20. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568.
    doi pubmed pmc
21. Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail. 2019;12(6):e005407.
    doi pubmed pmc
22. Jain A, Zahra F. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). In: StatPearls. Treasure Island (FL). 2024.
    pubmed
23. Spencer-Bonilla G, Njoroge JN, Pearson K, Witteles RM, Aras MA, Alexander KM. Racial and ethnic disparities in transthyretin cardiac amyloidosis. Curr Cardiovasc Risk Rep. 2021;15(6):8.
    doi pubmed pmc
24. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018;18(Suppl 2):s30-s35.
    doi pubmed pmc
25. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28(1):10-21.
    doi pubmed pmc
26. Obi CA, Mostertz WC, Griffin JM, Judge DP. ATTR epidemiology, genetics, and prognostic factors. Methodist Debakey Cardiovasc J. 2022;18(2):17-26.
    doi pubmed pmc
27. Bloom MW, Gorevic PD. Cardiac amyloidosis. Ann Intern Med. 2023;176(3):ITC33-ITC48.
    doi pubmed
28. Bianchi G, Kumar S. Systemic amyloidosis due to clonal plasma cell diseases. Hematol Oncol Clin North Am. 2020;34(6):1009-1026.
    doi pubmed
29. Tavares S, Dirksen A. Cardiac amyloidosis at a glance. Br J Nurs. 2024;33(9):424-429.
    doi pubmed
30. Jin FQ, Kakkad V, Bradway DP, LeFevre M, Kisslo J, Khouri MG, Trahey GE. Evaluation of myocardial stiffness in cardiac amyloidosis using acoustic radiation force impulse and natural shear wave imaging. Ultrasound Med Biol. 2023;49(8):1719-1727.
    doi pubmed pmc
31. Gertz MA. Cardiac Amyloidosis. Heart Fail Clin. 2022;18(3):479-488.
    doi pubmed pmc
32. Pucci A, Aimo A, Musetti V, Barison A, Vergaro G, Genovesi D, Giorgetti A, et al. Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis. J Am Heart Assoc. 2021;10(20):e020358.
    doi pubmed pmc
33. Laptseva N, Rossi VA, Sudano I, Schwotzer R, Ruschitzka F, Flammer AJ, Duru F. Arrhythmic manifestations of cardiac amyloidosis: challenges in risk stratification and clinical management. J Clin Med. 2023;12(7):2581.
    doi pubmed pmc
34. Kalola UK, Pellegrini MV. Patisiran. In: StatPearls. Treasure Island (FL). 2024.
    pubmed
35. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118(18):3517-3535.
    doi pubmed pmc
36. Saito Y, Nakamura K, Ito H. Molecular mechanisms of cardiac amyloidosis. Int J Mol Sci. 2021;23(1):25.
    doi pubmed pmc
37. Yilmaz A, Bauersachs J, Bengel F, Buchel R, Kindermann I, Klingel K, Knebel F, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110(4):479-506.
    doi pubmed pmc
38. Mesquita ET, Jorge AJL, Souza CVJ, Andrade TR. Cardiac amyloidosis and its new clinical phenotype: heart failure with preserved ejection fraction. Arq Bras Cardiol. 2017;109(1):71-80.
    doi pubmed pmc
39. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019;6(6):1128-1139.
    doi pubmed pmc
40. Imdad U. Amyloidosis of the heart: a comprehensive review. Cureus. 2023;15(2):e35264.
    doi pubmed pmc
41. Hanif MA, Omasan Mene-Afejuku T, Chandler O, Diaz Fraga J. Cardiac amyloidosis: a diagnostic dilemma and the role of a novel electrocardiogram criterion. Cureus. 2022;14(7):e26561.
    doi pubmed pmc
42. Khanna S, Lo P, Cho K, Subbiah R. Ventricular arrhythmias in cardiac amyloidosis: a review of current literature. Clin Med Insights Cardiol. 2020;14:1179546820963055.
    doi pubmed pmc
43. Machraa A, Ben Brahim W, Sidaty O, Fellat R, Fellat N. Sustained ventricular arrhythmia and sinus node dysfunction revealing a cardiac amyloidosis: A case report. Ann Med Surg (Lond). 2022;84:104888.
    doi pubmed pmc
44. Briasoulis A, Kourek C, Papamichail A, Loritis K, Bampatsias D, Repasos E, Xanthopoulos A, et al. Arrhythmias in patients with cardiac amyloidosis: a comprehensive review on clinical management and devices. J Cardiovasc Dev Dis. 2023;10(8):337.
    doi pubmed pmc
45. Cheng Z, Zhu K, Tian Z, Zhao D, Cui Q, Fang Q. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2013;18(2):157-162.
    doi pubmed pmc
46. Oye M, Richardson A, Sadic E, Alkhasawneh A, Velarde G. Cardiac amyloidosis presenting as biventricular systolic heart failure. Case Rep Cardiol. 2021;2021:6671469.
    doi pubmed pmc
47. Roginic S, Vinter O, Trbusic M, Roginic M, Catic Cuti E. Cardiac amyloidosis detected on imaging of patients with heart failure. Am J Case Rep. 2020;21:e926290.
    doi pubmed pmc
48. Jaiswal V, Agrawal V, Khulbe Y, Hanif M, Huang H, Hameed M, Shrestha AB, et al. Cardiac amyloidosis and aortic stenosis: a state-of-the-art review. Eur Heart J Open. 2023;3(6):oead106.
    doi pubmed pmc
49. Nasrullah A, Javed A, Jayakrishnan TT, Brumbaugh A, Sandhu A, Hardman B. AL type cardiac amyloidosis: a devastating fatal disease. J Community Hosp Intern Med Perspect. 2021;11(3):407-412.
    doi pubmed pmc
50. Donnellan E, Wazni OM, Hanna M, Elshazly MB, Puri R, Saliba W, Kanj M, et al. Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol. 2020;6(9):1118-1127.
    doi pubmed
51. Mitrani LR, De Los Santos J, Driggin E, Kogan R, Helmke S, Goldsmith J, Biviano AB, et al. Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding. Amyloid. 2021;28(1):30-34.
    doi pubmed pmc
52. Hartnett J, Jaber W, Maurer M, Sperry B, Hanna M, Collier P, Patel DR, et al. Electrophysiological manifestations of cardiac amyloidosis: JACC: CardioOncology State-of-the-Art review. JACC CardioOncol. 2021;3(4):506-515.
    doi pubmed pmc
53. Raval M, Siddiq S, Sharma K, Sanghvi L, Jain A, Patel S, Trivedi J, et al. A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies. F1000Res. 2023;12:192.
    doi pubmed pmc
54. Lizewska-Springer A, Slawinski G, Lewicka E. Arrhythmic sudden cardiac death and the role of implantable cardioverter-defibrillator in patients with cardiac amyloidosis-a narrative literature review. J Clin Med. 2021;10(9):1858.
    doi pubmed pmc
55. Kim EJ, Holmes BB, Huang S, Lugo R, Al Aboud A, Goodman S, Hung RR, et al. Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. Europace. 2020;22(8):1216-1223.
    doi pubmed
56. Rossi M, Varra GG, Porcari A, Saro R, Pagura L, Lalario A, Dore F, et al. Re-definition of the epidemiology of cardiac amyloidosis. Biomedicines. 2022;10(7):1566.
    doi pubmed pmc
57. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075.
    doi pubmed pmc
58. Papathanasiou M, Carpinteiro A, Rischpler C, Hagenacker T, Rassaf T, Luedike P. Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist. Int J Cardiol Heart Vasc. 2020;28:100519.
    doi pubmed pmc
59. Liang S, Liu Z, Li Q, He W, Huang H. Advance of echocardiography in cardiac amyloidosis. Heart Fail Rev. 2023;28(6):1345-1356.
    doi pubmed pmc
60. Maggialetti N, Torrente A, Lorusso G, Villanova I, Ficco M, Gravina M, Ferrari C, et al. Role of cardiovascular magnetic resonance in cardiac amyloidosis: a narrative review. J Pers Med. 2024;14(4):407.
    doi pubmed pmc
61. Khor YM, Cuddy SAM, Singh V, Falk RH, Di Carli MF, Dorbala S. (99m)Tc bone-avid tracer cardiac scintigraphy: role in noninvasive diagnosis of transthyretin cardiac amyloidosis. Radiology. 2023;306(2):e221082.
    doi pubmed pmc
62. Jiang S, Zhang L, Wang J, Li X, Hu S, Fu Y, Wang X, et al. Differentiating between cardiac amyloidosis and hypertrophic cardiomyopathy on non-contrast cine-magnetic resonance images using machine learning-based radiomics. Front Cardiovasc Med. 2022;9:1001269.
    doi pubmed pmc
63. Gill SS, Fellin E, Stampke L, Zhao Y, Masri A. Clinical clues and diagnostic workup of cardiac amyloidosis. Methodist Debakey Cardiovasc J. 2022;18(2):36-46.
    doi pubmed pmc
64. Asadian S, Farzin M, Tabesh F, Rezaeian N, Bakhshandeh H, Hosseini L, Toloueitabar Y, et al. The auxiliary role of cardiac magnetic resonance feature-tracking parameters in the differentiation between cardiac amyloidosis and constrictive pericarditis. Cardiol Res Pract. 2021;2021:2045493.
    doi pubmed pmc
65. Meaney E, Shabetai R, Bhargava V, Shearer M, Weidner C, Mangiardi LM, Smalling R, et al. Cardiac amyloidosis, contrictive pericarditis and restrictive cardiomyopathy. Am J Cardiol. 1976;38(5):547-556.
    doi pubmed
66. Ashraf I, Peck MM, Maram R, Mohamed A, Ochoa Crespo D, Kaur G, Malik BH. Association of arrhythmias in cardiac amyloidosis and cardiac sarcoidosis. Cureus. 2020;12(8):e9842.
    doi pubmed pmc
67. Yazaki M, Higuchi K. [Senile systemic amyloidosis]. Brain Nerve. 2014;66(7):817-826.
    pubmed
68. Sobue Y, Takemura G, Kawamura S, Yano T, Kanamori H, Morimoto SI, Matsuo H. Coexistence of amyloidosis and light chain deposition disease in the heart. Cardiovasc Pathol. 2021;51:107315.
    doi pubmed
69. Melero Polo J, Roteta Unceta-Barrenechea A, Revilla Marti P, Perez-Palacios R, Gracia Gutierrez A, Bueno Juana E, Andres Gracia A, et al. Echocardiographic markers of cardiac amyloidosis in patients with heart failure and left ventricular hypertrophy. Cardiol J. 2023;30(2):266-275.
    doi pubmed pmc
70. Scheel PJ, 3rd, Mukherjee M, Hays AG, Vaishnav J. Multimodality imaging in the evaluation and prognostication of cardiac amyloidosis. Front Cardiovasc Med. 2022;9:787618.
    doi pubmed pmc
71. Stern LK, Patel J. Cardiac amyloidosis treatment. Methodist Debakey Cardiovasc J. 2022;18(2):59-72.
    doi pubmed pmc
72. Perfetto F, Zampieri M, Fumagalli C, Allinovi M, Cappelli F. Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. Intern Emerg Med. 2022;17(4):957-969.
    doi pubmed pmc
73. Macedo AVS, Schwartzmann PV, de Gusmao BM, Melo MDT, Coelho-Filho OR. Advances in the treatment of cardiac amyloidosis. Curr Treat Options Oncol. 2020;21(5):36.
    doi pubmed pmc
74. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132-142.
    doi pubmed
75. Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553-1565.
    doi pubmed pmc
76. Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Conceicao I, Di Carli M, et al. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024;26(2):397-410.
    doi pubmed
77. Sousa M, Monohan G, Rajagopalan N, Grigorian A, Guglin M. Heart transplantation in cardiac amyloidosis. Heart Fail Rev. 2017;22(3):317-327.
    doi pubmed
78. Alexander KM, Witteles RM. Management of cardiac amyloidosis: Do's and Don'ts. Can J Cardiol. 2020;36(3):444-446.
    doi pubmed
79. Schilling M. [Gene therapy options for hereditary transthyretin-related amyloidosis]. Nervenarzt. 2022;93(6):557-565.
    doi pubmed
80. Minnema MC, Dispenzieri A, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, Grogan M, et al. Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial. JACC CardioOncol. 2022;4(4):474-487.
    doi pubmed pmc
81. De Michieli L, Cipriani A, Iliceto S, Dispenzieri A, Jaffe AS. Cardiac troponin in patients with light chain and transthyretin cardiac amyloidosis: JACC: CardioOncology State-of-the-Art review. JACC CardioOncol. 2024;6(1):1-15.
    doi pubmed pmc
82. Basset M, Milani P, Foli A, Nuvolone M, Benvenuti P, Nanci M, Fabris F, et al. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival. Blood. 2022;140(18):1964-1971.
    doi pubmed
83. Duca F, Snidat A, Binder C, Rettl R, Dachs TM, Seirer B, Camuz-Ligios L, et al. Hemodynamic profiles and their prognostic relevance in cardiac amyloidosis. J Clin Med. 2020;9(4):1093.
    doi pubmed pmc
84. Kim YJ, Ha S, Kim YI. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis. J Nucl Cardiol. 2020;27(1):123-132.
    doi pubmed
85. Jung MH, Chang S, Han EJ, Youn JC. Multimodal imaging and biomarkers in cardiac amyloidosis. Diagnostics (Basel). 2022;12(3):627.
    doi pubmed pmc
86. Mut F, Carvajal I, Camilletti J, Erriest J, Alexanderson E, Grossman GB. Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group. J Nucl Cardiol. 2023;30(4):1592-1601.
    doi pubmed pmc
87. Vergaro G, Aimo A, Barison A, Genovesi D, Buda G, Passino C, Emdin M. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol. 2020;27(17):1806-1815.
    doi pubmed
88. Takashio S, Morioka M, Ishii M, Morikawa K, Hirakawa K, Hanatani S, Oike F, et al. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2023;10(4):2319-2329.
    doi pubmed pmc
89. Vergaro G, Castiglione V, Aimo A, Prontera C, Masotti S, Musetti V, Nicol M, et al. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis. Eur J Heart Fail. 2023;25(3):335-346.
    doi pubmed
90. Chacko L, Martone R, Cappelli F, Fontana M. Cardiac amyloidosis: updates in imaging. Curr Cardiol Rep. 2019;21(9):108.
    doi pubmed pmc
91. Alreshq R, Ruberg FL. Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies. Curr Opin Cardiol. 2021;36(3):309-317.
    doi pubmed pmc
92. Zhang W, Ding J, Wang W, Wang D, Pan Y, Xu D. Status and future directions of therapeutics and prognosis of cardiac amyloidosis. Ther Clin Risk Manag. 2023;19:581-597.
    doi pubmed pmc
93. Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, et al. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood. 2018;131(14):1568-1575.
    doi pubmed
94. Morfino P, Aimo A, Vergaro G, Sanguinetti C, Castiglione V, Franzini M, Perrone MA, et al. Transthyretin stabilizers and seeding inhibitors as therapies for amyloid transthyretin cardiomyopathy. Pharmaceutics. 2023;15(4):1129.
    doi pubmed pmc
95. Patel RK, Fontana M, Ruberg FL. Cardiac amyloidosis: multimodal imaging of disease activity and response to treatment. Circ Cardiovasc Imaging. 2021;14(6):e009025.
    doi pubmed pmc
96. Faja S, Clarkson T, Gilbert R, Vaidyanathan A, Greco G, Rueda MR, Combita LM, et al. A preliminary randomized, controlled trial of executive function training for children with autism spectrum disorder. Autism. 2022;26(2):346-360.
    doi pubmed pmc

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cardiology Research is published by Elmer Press Inc.